Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.

Insulin API is a relatively concentrated industry in China, The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi several companies but their products are for their own use. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API
The overall domestic policy for the development of insulin API is supported. Local governments have a lot of policies to support the development of the industry. But in recent years environmental protection requirements for the fermentation industry are also getting higher and higher.

According to this study, over the next five years the Insulin API market will register a 4.2% CAGR in terms of revenue, the global market size will reach USD 2120 million by 2024, from USD 1660 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Insulin API business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Insulin API market by product type, application, key manufacturers and key regions and countries.

This study considers the Insulin API value and volume generated from the sales of the following segments-

Segmentation by product type- breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Regular Human Insulin
Insulin Analogue
Segmentation by application- breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Fast-acting
Premix
Long-acting

This report also splits the market by region- Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report- Breakdown data in in Chapter 3.
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
United Laboratory
Biocon
Torrent Pharma
Amphastar
Ganlee
Julphar Diabetes
Wockhardt

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Insulin API consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Insulin API market by identifying its various subsegments.
Focuses on the key global Insulin API manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Insulin API with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Insulin API submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.